Tips from the American Journal of...(FPR-1-deficient mice unlike annexin A1-n...)

The data by Gastardelo et al "provide in vivo evidence that endogenous annexin A1 is an essential mediator for homeostasis during the inflammatory process." They go on to propose "that these experimental findings may impact the development of novel therapeutics based on the anti-migratory actions of annexin A1."

Gastardelo TS, Damazo AS, Dalli J, Flower RJ, Perretti M, Oliani SM: Functional and ultrastrutural analysis of annexin A1 and its receptor in extravasting neurophils during inflammation. Am J Pathol 2009, 174:177-183

Cyclophilin B Is a Possible New Target for Treating Breast Cancer

Dr. Charles Clevenger and colleagues at Northwestern University have uncovered that cyclophilin B may contribute to progression in breast cancer. Their report can be found in the January 2009 issue of The American Journal of Pathology.

The protein cyclophilin B affects cell division, motility, and death, all of which are altered in cancerous cells. To explore the role of cyclophilin B-mediated gene regulation in breast cancer, Dr. Clevenger and colleagues inhibited cyclophilin B expression in breast cancer cells. They found that absence of cyclophilin B impacted 27 different protein networks and decreased cell proliferation, motility, and tumorigenesis. In addition, in human breast tissue, increases in cyclophilin B protein levels correlated with the presence of breast cancer metastases.

The studies by Fang et al "demonstrate that a decrease in cyclophilin B levels can profoundly alter the expression of genes and cellular functions relevant to the pathogenesis and progression of breast cancer. In this regard, the development of additional pharmacologic agents that specifically target each of the cyclophilins may h
'/>"/>